JEWJITSU PEPTIDES: Research roundup on engineered collagen, plant chemocarriers, and LCN2 in cardio-kidney links

The first study reports engineering of Pichia pastoris strains to secrete a continuous fragment of human type III collagen corresponding to a defined 585‑amino‑acid sequence. The authors used proteolytic selection and LC‑MS/MS to identify the continuous product, optimized signal peptides to improve secretion, and developed strains with high production levels. Purification by multimodal chromatography yielded material with reported high purity and low endotoxin, and biophysical assays showed enhanced thermal stability. The authors noted that circular dichroism did not indicate a canonical triple‑helix, while FTIR supported preservation of key backbone structures. Cell assays reported cytocompatibility and effects on human skin fibroblast viability, adhesion, and migration. The paper frames a scalable production approach but also documents structural differences from canonical collagen and thus highlights the need for further characterization before specific applications are inferred.

The second paper describes a chemical‑carrier strategy to improve intracellular delivery and functional potency of peptide inhibitors targeting MYC–coactivator interfaces in plants. The team established a multi‑step, target‑guided screening workflow that combined primary and secondary AlphaScreen assays with a tertiary assay of MYC–MED25 interaction and included screening of an approved‑drug library and structure‑activity optimization. They identified an aromatic derivative with cell‑penetrating activity in Arabidopsis and showed that conjugation to this chemocarrier markedly enhanced delivery and efficacy of various peptide scaffolds, including cyclic and stapled peptides, by orders of magnitude. The authors present this as a practical chemical modality to access transcription factor–cofactor interfaces in planta. Limitations include that the demonstrations were performed in plant systems and focused on specific MYC interactions, so broader applicability and mechanistic details in other organisms remain to be established.

The third report investigates lipocalin‑2 (LCN2) in the context of cardiovascular–kidney–metabolic syndrome among people with type 2 diabetes. In a cohort analysis the authors measured serum LCN2 and report associations between elevated LCN2 and presence of diabetic kidney disease (DKD) or coronary artery disease (CAD), with correlations to DKD severity and natriuretic peptide levels; regression analysis is described as indicating LCN2 as an independent risk factor for DKD or CAD, and mediation analysis suggested LCN2 may partially mediate the bidirectional link between DKD and CAD. Complementary animal and cell experiments showed upregulation of LCN2 in heart and kidney tissues of diabetic mice and dose‑dependent increases in inflammatory mRNA in renal tubular and cardiomyocyte cell lines exposed to recombinant LCN2. The study combines observational and experimental data but cannot by itself establish causal pathways in humans and calls for additional mechanistic and translational work.